About Vical Incorporated
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: VICL
- CUSIP: 92560210
- Previous Close: $2.16
- 50 Day Moving Average: $2.26
- 200 Day Moving Average: $2.84
- 52-Week Range: $2.05 - $4.80
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.70
- P/E Growth: 0.00
- Market Cap: $24.20M
- Outstanding Shares: 11,049,000
- Beta: 2.07
- Net Margins: -47.06%
- Return on Equity: -19.11%
- Return on Assets: -17.57%
Companies Related to Vical Incorporated:
- Current Ratio: 11.87%
- Quick Ratio: 11.87%
What is Vical Incorporated's stock symbol?
Vical Incorporated trades on the NASDAQ under the ticker symbol "VICL."
Where is Vical Incorporated's stock going? Where will Vical Incorporated's stock price be in 2017?
1 analysts have issued 1-year price objectives for Vical Incorporated's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Vical Incorporated's share price to reach $8.00 in the next year.
When will Vical Incorporated announce their earnings?
Vical Incorporated is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns Vical Incorporated stock?
Vical Incorporated's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (9.11%) and Renaissance Technologies LLC (3.55%). Company insiders that own Vical Incorporated stock include Anthony Alan Ramos, Gary A Lyons, Igor Bilinsky, Lawrence Russell Smith, R Gordon Douglas, Robert C Merton and Vijay B Samant.
Who bought Vical Incorporated stock? Who is buying Vical Incorporated stock?
Vical Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and FMR LLC. Company insiders that have bought Vical Incorporated stock in the last two years include Gary A Lyons, R Gordon Douglas, Robert C Merton and Vijay B Samant.
How do I buy Vical Incorporated stock?
Shares of Vical Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Vical Incorporated stock cost?
One share of Vical Incorporated stock can currently be purchased for approximately $2.19.